Key result
Recent clinical trials indicate that lowering blood pressure, rather than the specific medication chosen, accounts for most cardiovascular benefits, though ACE inhibitors and low-dose combinations are recommended as initial therapy.
Why the study?
How do recent clinical trial results impact national recommendations for the pharmacological management of hypertension?
How do recent clinical trial results impact national recommendations for the pharmacological management of hypertension?
Recent clinical trials support the use of ACE inhibitors, ARBs, diuretics, and beta blockers as initial therapy for hypertension, emphasizing the need for combination therapy to reach blood pressure goals.
Answers are grounded in this paper and cite their sources.
Supports BP lowering as primary goal in hypertension; extends trial evidence by reinforcing ACE inhibitors and combinations in national guidelines.
Numerous hypertension treatment trials have been reported during the past several years. In comparative studies it has been shown that the use of diuretics or diuretics/beta blockers has resulted in a reduction in morbidity/mortality equivalent to the use of other antihypertensive medications. This is true in both young and elderly patients. In one large 8-year study in diabetics, the use of a beta blocker/diuretic combination was shown to be as effective in reducing overall cardiovascular events as an angiotensin-converting enzyme (ACE) inhibitor/diuretic treatment program. Although most data indicate that the degree of blood pressure lowering accounts for most of the benefit, there are some differences in outcome that may be explained by different mechanisms of drug action. For example: 1) diuretics are more effective in preventing heart failure and overall cardiovascular events than alpha blockers; 2) an ACE inhibitor-based program is more effective in the elderly in reducing myocardial infarctions and heart failure than a calcium channel blocker-based program; and 3) a nondihydropyridine is more effective in reducing strokes, but less effective in preventing myocardial infarctions or heart failure, than a program based on diuretic therapy. There is also abundant evidence that the use of ACE inhibitors may prevent the occurrence of diabetes in hypertensive individuals and will reduce cardiovascular events in diabetics. Finally, the angiotensin receptor blockers have been shown to slow the progression of renal disease and prevent the occurrence of end-stage renal disease when compared to treatment regimens that do not include an angiotensin receptor blocker or ACE inhibitor. Updated treatment recommendations should include an ACE inhibitor and possibly an angiotensin receptor blocker along with diuretics and beta blockers as initial therapy. In addition, recommendations for the use of multiple-drug therapy have been reinforced by recent trials. Goal pressures are not readily achieved with monotherapy, especially in high-risk patients.
No takes yet. Share an insight, caveat, or question.
Marvin Moser (2002) conducted a review in Hypertension. Antihypertensive therapy (various classes) vs. Placebo or alternative antihypertensive classes was evaluated. Recent clinical trials indicate that lowering blood pressure, rather than the specific medication chosen, accounts for most cardiovascular benefits, though ACE inhibitors and low-dose combinations are recommended as initial therapy.
Synapse has enriched 10 related papers. Consider them for comparative context: